Skip to Content
Merck
CN

382170

Histone Deacetylase Inhibitor IV

The Histone Deacetylase Inhibitor IV, also referenced under CAS 537034-15-4, controls the biological activity of Histone Deacetylase. This small molecule/inhibitor is primarily used for Cell Structure applications.

Synonym(s):

Histone Deacetylase Inhibitor IV, N¹-(2-Aminophenyl)-N⁷-phenylheptanediamide

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C19H23N3O2
CAS Number:
Molecular Weight:
325.40
UNSPSC Code:
12352200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Histone Deacetylase Inhibitor IV, The Histone Deacetylase Inhibitor IV, also referenced under CAS 537034-15-4, controls the biological activity of Histone Deacetylase. This small molecule/inhibitor is primarily used for Cell Structure applications.

InChI key

ZAIULUYKQLVQFH-UHFFFAOYSA-N

InChI

1S/C19H23N3O2/c20-16-11-7-8-12-17(16)22-19(24)14-6-2-5-13-18(23)21-15-9-3-1-4-10-15/h1,3-4,7-12H,2,5-6,13-14,20H2,(H,21,23)(H,22,24)

assay

≥97% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

beige

solubility

DMSO: 100 mg/mL
methanol: 5 mg/mL

shipped in

ambient

storage temp.

−20°C

Quality Level

Biochem/physiol Actions

Cell permeable: yes
Primary Target
Histone Deacetylase
Product does not compete with ATP.
Reversible: no

Disclaimer

Toxicity: Harmful (C)

General description

A cell-permeable pimeloylanilide compound that acts as a FXN- (frataxin gene) specific HDAC (histone deacetylase) inhibitor. Reverses the silencing of FXN transcription in FRDA (Friedreich′s ataxia) cells (~3-fold increase of FXN mRNA at 5 µM in primary FRDA lymphocytes and ~3-fold frataxin expression in FRDA cell line at 2.5 µM) due to hypoacetylation of histones H3 and H4 by increasing acetylation at H3K14, H4K5 and H4K12, without significant changes in acetylation at H3K9, H4K8 and H4K16. In comparison, Trichostatin-A (Cat. No. 647925 and 647926) and SAHA, two other commonly used HDAC inhibitors, exhibit no effect on FXN transcription.

Other Notes

Herman, D., et al. 2006. Nat. Chem. Biol.2, 551.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service